BACKGROUND: Smoking cessation programmes were first introduced in Iran in 1997. To date a number of types of nicotine replacement therapy have been prescribed. OBJECTIVE: To evaluate the effectiveness of varenicline for tobacco cessation. METHODS: This was a randomised parallel clinical study conducted in 2010. Participants were smokers willing to quit who were visiting a smoking cessation clinic for the first time and were randomly divided into three groups: all three groups received brief counselling on cessation, Group 2 received nicotine patches and Group 3 was prescribed varenicline for 8 weeks. RESULTS: There were 272 participants in the study: 91 in Group 1, 92 in Group 2 and 89 in Group 3. At the end of the first month, 128 of the 272 subjects (47.1%) succeeded in quitting: 17 (18.7%) in Group 1, 60 (65.2%) in Group 2 and 51 (57.3%) in Group 3 (P = 0.000). At follow-up after 12 months, 58 subjects (21.3%) remained smoke-free, of whom 6 (6.6%) were in Group 1, 23 (25%) in Group 2 and 29 (32.6%) in Group 3 (P = 0.000). CONCLUSION: In the study, varenicline treatment was slightly more effective than but not significantly different from nicotine replacement therapy.
RCT Entities:
BACKGROUND: Smoking cessation programmes were first introduced in Iran in 1997. To date a number of types of nicotine replacement therapy have been prescribed. OBJECTIVE: To evaluate the effectiveness of varenicline for tobacco cessation. METHODS: This was a randomised parallel clinical study conducted in 2010. Participants were smokers willing to quit who were visiting a smoking cessation clinic for the first time and were randomly divided into three groups: all three groups received brief counselling on cessation, Group 2 received nicotine patches and Group 3 was prescribed varenicline for 8 weeks. RESULTS: There were 272 participants in the study: 91 in Group 1, 92 in Group 2 and 89 in Group 3. At the end of the first month, 128 of the 272 subjects (47.1%) succeeded in quitting: 17 (18.7%) in Group 1, 60 (65.2%) in Group 2 and 51 (57.3%) in Group 3 (P = 0.000). At follow-up after 12 months, 58 subjects (21.3%) remained smoke-free, of whom 6 (6.6%) were in Group 1, 23 (25%) in Group 2 and 29 (32.6%) in Group 3 (P = 0.000). CONCLUSION: In the study, varenicline treatment was slightly more effective than but not significantly different from nicotine replacement therapy.
Authors: Kevin M Gray; Erin A McClure; Nathaniel L Baker; Karen J Hartwell; Matthew J Carpenter; Michael E Saladin Journal: Addiction Date: 2015-03-29 Impact factor: 6.526
Authors: Sherry A McKee; Philip H Smith; Mira Kaufman; Carolyn M Mazure; Andrea H Weinberger Journal: Nicotine Tob Res Date: 2015-10-06 Impact factor: 4.244
Authors: Gholamreza Heydari; Mohammadreza Masjedi; Arezoo Ebn Ahmady; Scott J Leischow; Harry A Lando; Mohammad B Shadmehr; Lida Fadaizadeh Journal: Int J Prev Med Date: 2015-08-10
Authors: Gholamreza Heydari; Mohammadreza Masjedi; Arezoo Ebn Ahmady; Scott J Leischow; A Lando Harry; Mohammad B Shadmehr; Lida Fadaizadeh Journal: Int J Prev Med Date: 2015-09-01
Authors: Mahmood Karimy; Shamsaddin Niknami; Ali Reza Heidarnia; Ibrahim Hajizadeh; Ali Montazeri Journal: Iran Red Crescent Med J Date: 2013-03-05 Impact factor: 0.611
Authors: Gholamreza Heydari; Mohammadreza Masjedi; Arezoo Ebn Ahmady; Scott J Leischow; Harry A Lando; Mohammad Behgam Shadmehr; Lida Fadaizadeh Journal: Int J Prev Med Date: 2014-06